MS4A1 and non-Hodgkin lymphoma: Roche’s CD3/CD20 bispecific antibody RO7082859 was approved in China on 9 September 2020 for the treatment of diffuse large B-cell lymphoma, further improving the treatment of non-Hodgkin lymphoma.